Cellectis S.A. ADR (CLLS) Stock Price, Quote & News

Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 1 81 69 16 00

Website: www.cellectis.com

Address:

8, rue de la Croix Jarry, Paris, France

StocktwitsEarnings Mar. 20 at 11:57 AM

$CLLS Q4 '25 Earnings Results & Recap Cellectis anticipates continued significant expenses and operating losses for the foreseeable future, requiring additional funding that may not be available on acceptable terms or at all.

0 · Reply

Nanu108 Mar. 20 at 12:30 AM

$CLLS I'm in for 10000 shares.

0 · Reply

focafoca99 Mar. 12 at 10:25 PM

$CLLS just set the clock: Q4 and full-year 2025 numbers on March 19, then the call on March 20.

0 · Reply

rlkloehn Mar. 12 at 9:59 PM

$CLLS will report financial results for the fourth quarter and full year 2025 ending December 31, 2025 on Thursday, March 19, 2026 after the close of the US market.

1 · Reply

rlkloehn Mar. 9 at 4:39 PM

$CLLS The 28th annual Barclays Global Healthcare conference will be held from March 10 to 12, 2026 in Miami, FL. Arthur Stril, Chief Financial Officer and Chief Business Officer, will participate in informal discussions on March 11, 2026 at 10:00 AM ET. He will also hold appointments with investors.

1 · Reply

rlkloehn Mar. 9 at 4:38 PM

$CLLS The Citizens Life Sciences 2026 conference will be held on March 10 and 11, 2026 in Miami Beach, United States. André Choulika, General Manager, and Arthur Stril, Chief Financial Officer and Sales Director of Cellectis, will be present. They will participate in an informal discussion on March 11, 2026 at 4:35 p.m. (Eastern Time) and hold meetings with investors.

0 · Reply

focafoca99 Mar. 4 at 11:33 PM

$CLLS published monthly capital data: 100,590,994 shares and 105,825,561 voting rights as of Feb 28, so the structure update is very explicit.

0 · Reply

OfficialStocktwitsUser Feb. 23 at 11:48 PM

$CLLS RSI: 53.65, MACD: -0.0803 Vol: 0.22, MA20: 3.82, MA50: 4.23 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing Feb. 18 at 11:37 PM

$CLLS Current Stock Price: $4.05 Contracts to trade: $5.0 CLLS Feb 20 2026 Call Entry: $0.05 Exit: $0.06 ROI: 27% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ChartVader Feb. 17 at 8:49 AM

$CLLS Pre-revenue biotech; early-stage

0 · Reply

Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript

Mar 19, 2026, 7:21 PM EDT - 2 days ago

Market Cap	185.64M
Revenue (ttm)	49.22M
Net Income (ttm)	-36.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-74.69%
Debt to Equity Ratio	0.81

Volume	103,000
Avg Vol	45,872
Day's Range	N/A - N/A
Shares Out	55.58M
Stochastic %K	18%
Beta	2.85
Analysts	Strong Sell
Price Target	$7.40